{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:08:28Z","timestamp":1761102508869,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170180","82170180","82170180"],"award-info":[{"award-number":["82170180","82170180","82170180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-022-04473-5","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:03:17Z","timestamp":1670292197000},"page":"5513-5529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K\/AKT and p38\/MAPK signaling"],"prefix":"10.1007","volume":"149","author":[{"given":"Guangchao","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengya","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinshui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"4473_CR1","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","volume":"105","author":"EM Algarin","year":"2020","unstructured":"Algarin EM, Diaz-Tejedor A, Mogollon P, Hernandez-Garcia S, Corchete LA, San-Segundo L, Martin-Sanchez M, Gonzalez-Mendez L, Schoumacher M, Banquet S et al (2020) Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica 105:e116\u2013e120. https:\/\/doi.org\/10.3324\/haematol.2018.212308","journal-title":"Haematologica"},{"key":"4473_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN, Chapuy B et al (2019) Targeted inhibition of PI3Kalpha\/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood 133:70\u201380. https:\/\/doi.org\/10.1182\/blood-2018-08-872465","journal-title":"Blood"},{"key":"4473_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA (2019) Bruton tyrosine kinase inhibitors: present and future. Cancer J 25:386\u2013393. https:\/\/doi.org\/10.1097\/PPO.0000000000000412","journal-title":"Cancer J"},{"key":"4473_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1215637","journal-title":"N Engl J Med"},{"key":"4473_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","volume":"8","author":"S Cang","year":"2015","unstructured":"Cang S, Iragavarapu C, Savooji J, Song Y, Liu D (2015) ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol 8:129. https:\/\/doi.org\/10.1186\/s13045-015-0224-3","journal-title":"J Hematol Oncol"},{"key":"4473_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1042\/BJ20100323","volume":"429","author":"A Cuadrado","year":"2010","unstructured":"Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK signalling. Biochem J 429:403\u2013417. https:\/\/doi.org\/10.1042\/BJ20100323","journal-title":"Biochem J"},{"key":"4473_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","volume":"130","author":"MS Davids","year":"2017","unstructured":"Davids MS (2017) Targeting BCL-2 in B-cell lymphomas. Blood 130:1081\u20131088. https:\/\/doi.org\/10.1182\/blood-2017-04-737338","journal-title":"Blood"},{"key":"4473_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88\u201392. https:\/\/doi.org\/10.1038\/nature08638","journal-title":"Nature"},{"key":"4473_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Orelabrutinib: first approval. Drugs 81:503\u2013507. https:\/\/doi.org\/10.1007\/s40265-021-01482-5","journal-title":"Drugs"},{"key":"4473_CR10","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000247","author":"K Dunleavy","year":"2021","unstructured":"Dunleavy K (2021) Double-hit lymphoma: optimizing therapy. Hematology. https:\/\/doi.org\/10.1182\/hematology.2021000247","journal-title":"Hematology"},{"key":"4473_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev 30:193\u2013204. https:\/\/doi.org\/10.1016\/j.ctrv.2003.07.007","journal-title":"Cancer Treat Rev"},{"key":"4473_CR12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"Friedberg JW (2017) How I treat double-hit lymphoma. Blood 130:590\u2013596. https:\/\/doi.org\/10.1182\/blood-2017-04-737320","journal-title":"Blood"},{"key":"4473_CR13","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J et al (2014) Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 370:2352\u20132354. https:\/\/doi.org\/10.1056\/NEJMc1402716","journal-title":"N Engl J Med"},{"key":"4473_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT (2018) Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 118:9\u201316. https:\/\/doi.org\/10.1038\/bjc.2017.434","journal-title":"Br J Cancer"},{"key":"4473_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/cdd.2017.179","volume":"25","author":"H Kalkavan","year":"2018","unstructured":"Kalkavan H, Green DR (2018) MOMP, cell suicide as a BCL-2 family business. Cell Death Differ 25:46\u201355. https:\/\/doi.org\/10.1038\/cdd.2017.179","journal-title":"Cell Death Differ"},{"key":"4473_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A (2020) Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis 11:941. https:\/\/doi.org\/10.1038\/s41419-020-03144-y","journal-title":"Cell Death Dis"},{"key":"4473_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-immunol-073119-095439","volume":"38","author":"S Kesavardhana","year":"2020","unstructured":"Kesavardhana S, Malireddi RKS, Kanneganti TD (2020) Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol 38:567\u2013595. https:\/\/doi.org\/10.1146\/annurev-immunol-073119-095439","journal-title":"Annu Rev Immunol"},{"key":"4473_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1385\/IR:23:2-3:147","volume":"23","author":"WN Khan","year":"2001","unstructured":"Khan WN (2001) Regulation of B lymphocyte development and activation by Bruton\u2019s tyrosine kinase. Immunol Res 23:147\u2013156. https:\/\/doi.org\/10.1385\/IR:23:2-3:147","journal-title":"Immunol Res"},{"key":"4473_CR19","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.3748\/wjg.v21.i15.4547","volume":"21","author":"FX Li","year":"2015","unstructured":"Li FX, Huang LZ, Dong C, Wang JP, Wu HJ, Shuang SM (2015) Down-regulation of aquaporin3 expression by lipopolysaccharide via p38\/c-Jun N-terminal kinase signalling pathway in HT-29 human colon epithelial cells. World J Gastroenterol 21:4547\u20134554. https:\/\/doi.org\/10.3748\/wjg.v21.i15.4547","journal-title":"World J Gastroenterol"},{"key":"4473_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","volume":"12","author":"W Li","year":"2019","unstructured":"Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, Greipp PT, Elsawa SF, Sotomayor EM, Gupta M (2019) Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol 12:73. https:\/\/doi.org\/10.1186\/s13045-019-0761-2","journal-title":"J Hematol Oncol"},{"key":"4473_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exphem.2021.10.006","volume":"105","author":"F Liu","year":"2022","unstructured":"Liu F, Zhao Q, Su Y, Lv J, Gai Y, Liu S, Lin H, Wang Y, Wang G (2022) Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. Exp Hematol 105:39\u201349. https:\/\/doi.org\/10.1016\/j.exphem.2021.10.006","journal-title":"Exp Hematol"},{"key":"4473_CR22","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, Caldwell JT, Xiang S, Zhang X, Chu R et al (2016) Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res 22:4440\u20134451. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3057","journal-title":"Clin Cancer Res"},{"key":"4473_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17:57. https:\/\/doi.org\/10.1186\/s12943-018-0779-z","journal-title":"Mol Cancer"},{"key":"4473_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S (2019) Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol 136:56\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"4473_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, Hamerschlak N (2018) BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol 11:65. https:\/\/doi.org\/10.1186\/s13045-018-0608-2","journal-title":"J Hematol Oncol"},{"key":"4473_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11899-018-0467-5","volume":"13","author":"J Rhodes","year":"2018","unstructured":"Rhodes J, Landsburg DJ (2018) Small-molecule inhibitors for the treatment of diffuse large B cell lymphoma. Curr Hematol Malig Rep 13:356\u2013368. https:\/\/doi.org\/10.1007\/s11899-018-0467-5","journal-title":"Curr Hematol Malig Rep"},{"key":"4473_CR27","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124:4622\u20134632. https:\/\/doi.org\/10.1002\/cncr.31646","journal-title":"Cancer"},{"key":"4473_CR28","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","volume":"127","author":"KJ Savage","year":"2016","unstructured":"Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL et al (2016) Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 127:2182\u20132188. https:\/\/doi.org\/10.1182\/blood-2015-10-676700","journal-title":"Blood"},{"key":"4473_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"key":"4473_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2013.11.019","volume":"344","author":"X Sui","year":"2014","unstructured":"Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C, Pan H (2014) p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett 344:174\u2013179. https:\/\/doi.org\/10.1016\/j.canlet.2013.11.019","journal-title":"Cancer Lett"},{"key":"4473_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","volume":"24","author":"F Vaillant","year":"2013","unstructured":"Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ et al (2013) Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24:120\u2013129. https:\/\/doi.org\/10.1016\/j.ccr.2013.06.002","journal-title":"Cancer Cell"},{"key":"4473_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-015-1778-8","volume":"15","author":"GG Vega","year":"2015","unstructured":"Vega GG, Aviles-Salas A, Chalapud JR, Martinez-Paniagua M, Pelayo R, Mayani H, Hernandez-Pando R, Martinez-Maza O, Huerta-Yepez S, Bonavida B et al (2015) P38 MAPK expression and activation predicts failure of response to CHOP in patients with diffuse large B-cell lymphoma. BMC Cancer 15:722. https:\/\/doi.org\/10.1186\/s12885-015-1778-8","journal-title":"BMC Cancer"},{"key":"4473_CR33","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1080\/10428194.2018.1563694","volume":"60","author":"Q Wang","year":"2019","unstructured":"Wang Q, Wan J, Zhang W, Hao S (2019) MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. Leuk Lymphoma 60:2170\u20132180. https:\/\/doi.org\/10.1080\/10428194.2018.1563694","journal-title":"Leuk Lymphoma"},{"key":"4473_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922\u2013926. https:\/\/doi.org\/10.1038\/nm.3884","journal-title":"Nat Med"},{"key":"4473_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01219-5","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Wang WH, Dong M, Ma SS, Zhang XD, Zhu LN, Niu ST, Ding MJ, Zhang JM, Zhang L et al (2022) Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. Invest New Drugs. https:\/\/doi.org\/10.1007\/s10637-022-01219-5","journal-title":"Invest New Drugs"},{"key":"4473_CR36","doi-asserted-by":"publisher","first-page":"8593","DOI":"10.2147\/OTT.S247429","volume":"13","author":"H Yang","year":"2020","unstructured":"Yang H, Zhang P, Li J, Gao Y, Zhao L, Li J, Guo M, Zhang J, Li H, Wang F et al (2020) Targeting PIN-1 attenuates GCB DLBCL cell proliferation through inhibition of PI3K\/AKT signaling. Onco Targets Ther 13:8593\u20138600. https:\/\/doi.org\/10.2147\/OTT.S247429","journal-title":"Onco Targets Ther"},{"key":"4473_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","volume":"21","author":"H Yu","year":"2021","unstructured":"Yu H, Wang X, Li J, Ye Y, Wang D, Fang W, Mi L, Ding N, Wang X, Song Y et al (2021) Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther Oncolytics 21:158\u2013170. https:\/\/doi.org\/10.1016\/j.omto.2021.03.015","journal-title":"Mol Ther Oncolytics"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04473-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:03:50Z","timestamp":1689768230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04473-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4473"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04473-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflicting interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the First Affiliated Hospital of Xiamen University Ethics Review Board. Informed consent was obtained from the patients before the collection of lymph node samples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}